Shedding light on Intercept’s opaque disclosure
Intercept’s woes have continued as a possible new liver toxicity signal was buried in a regulatory filing. What could this mean?
Could Alkermes’ new antipsychotic punch below its weight?
Approval of ALKS 3831 looks likely after Friday’s positive panel vote, but sales might disappoint.
Thinking the unthinkable on Covid vaccine approvals
With the EU regulator already reviewing two coronavirus vaccines, could it beat the US FDA to the punch?
FDA tightens up digital health oversight
Software-enabled medical devices pose unique challenges to regulators, and the US agency is getting serious about meeting them.
Abbott rides to the rescue with $5 Covid-19 test
The BinaxNow antigen test is fast and acceptably accurate – but above all, cheap.
Warp Speed keeps on giving
The latest Covid-19 vaccine award sees Glaxo and Sanofi score a $2.1bn windfall from the US government.
Market says meh to presidential drug pricing orders
There was a time when President Trump could mention drug pricing controls and move markets. Now, not so much.
US pursues pooled testing for Covid-19, and Quest benefits
Batch testing could allow large numbers of people to be ruled out as having Covid-19, but accuracy concerns remain.
